Status:
UNKNOWN
ALDH1A1 Expression in Invasive Mammary Carcinoma
Lead Sponsor:
Sohag University
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to dru...
Detailed Description
Breast cancer is one of the most common cancers among women. it is a heterogenous disease. several factors affect the prognosis of breast cancer. CSCs markers are one of the emerging prognostic biomar...
Eligibility Criteria
Inclusion
- Patients with invasive mammary carcinoma carcinoma and underwent surgery
Exclusion
- Cases received pre-operative chemotherapy or radiotherapy.
- Cases with insufficient clinical data.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06134570
Start Date
October 1 2023
End Date
June 1 2024
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Sohag, Egypt